Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Phase 3 study of ivacaftor in babies who have a CFTR gating mutation , protocol number Vertex VX15-770-124

  This two-part, open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of ivacaftor, as well as how the body processes the drug, in babies who have a CFTR gating mutation.

  • Age:

    0 Months to 12 Months

  • Mutation(s):

    One Copy F508del or No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    8

  • Length of Participation:

    24 weeks

• Mucociliary ClearanceEnrolling

  SHIP CT: Study of hypertonic saline in preschoolers , protocol number SHIP002

  This study is taking place in Europe, Australia and the U.S. It will look at the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in children with CF.

  • Age:

    3 Years to 5 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    6

  • Length of Participation:

    54 weeks

• Anti-InflammatoryEnrolling

  Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    6

  • Length of Participation:

    189 days

• Anti-InfectiveEnrolling

  Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis , protocol number Savara SAV005-04

  This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older with cystic fibrosis and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

  • Age:

    6 Years to 21 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    12 months

• ObservationalEnrolling

  Sweat chloride observational study , protocol number CHEC-OB-17

  This study is taking place at multiple care centers across the U.S. It will look at sweat chloride concentration in people who are currently taking CFTR modulators.

  • Age:

    4 Months and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    1

  • Length of Participation:

    1 days

• OtherEnrolling

  Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2

  This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    49 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.